The Effects of Atenolol and Metoprolol on Survival Rate of Patients with Mild-to-Moderate Chronic Heart Failure: A Comparative Study
Vera Celic, Biljana Pencic, Milica Dekleva, Sinisa Dimkovic, Maksimilijan Kocijancic
Clinical Medical Centre ”Dr. Dragisa Misovic” – Dendinje, Belgrade
Srp Arh Celok Lek. 133(5-6):242-7, 2005 May-Jun. Translation from Serbian.
Abstract
Regardless of its grounds and hospital treatments the sum of death outcomes caused by cardiovascular reasons is an indicator of survival rate for patients with mild-to-moderate chronic heart failure and is characterized as a combined case. The aim of this study was to investigate influence of metoprolol and atenolol on the combined case in patients with chronic heart failure. The study was comparative, prospective and randomised. The criteria for including in the study were: age of 70 years or less, NYHA functional class II and III, left ventricular ejection fraction ≤40%. One hundred and fifty patients who had been treated by angiotensin converting enzyme inhibitor and by diuretics were divided into three numerically equal therapeutic groups: patients treated by atenolol (”the atenolol group”), patients treated by metoprolol (”the metoprolol group”) and a control group of patients who were not treated by beta blockers. Effects of the treatment were observed for 12 months. The results were analyzed by the SPSS 10.0 statistical software. The cumulative survival rate of patients treated by metoprolol (88%) and by atenolol (78%) was greater than survival rate of patients from the control group (48%). Survival rate of patients treated by metoprolol was also greater then survival rate of patients treated by atenolol. Metoprolol significantly reduced the risk for occurrence of combined cases (71%) compared to atenolol (53%). Results of the study have shown that metoprolol and atenolol have a positive effect on the survival rate of patients with chronic heart failure though metoprolol’s effect is significantly better compared to atenolol.
Key words: chronic heart failure; beta-blockers; metoprolol; atenolol
Introduction
The most important pathophysiological process of chronic heart failure (CHF) is the process of remodeling of the heart ventricles. The remodeling starts and develops primarily due to angiotensins and catecholamines activities [1, 2]. The hypothesis that the medicines that inhibit or reverses the remodeling can prolong CHF patients’ lives got confirmed by the results of large studies on the angiotensin-converting enzyme inhibitors (ACE inhibitors) and beta blockers (β blockers). A long-term use of β blockers has a surprisingly positive effect on overall cardiovascular mortality and morbidity [3-5]. These effects have a solid confirmation only for carvedilol, metoprolol and bisoprolol at mild and moderate CHF, even though according to the professor John G. F. Cleland’s statements, atenolol, propranolol, acebutolol, bisoprolol and betaxolol are used in Europe and US as well [6, 7]. The main question is do different β blockers have a significantly different effect on the CHF patient’s survival rate [7, 8]. Results from the comparative studies (COMET and other) as well as from our study could give the answer on that question in the years that follow [9, 10].
Aim of the work
Aim of the study was to investigate and compare effect of atenolol and metoprolol on the survival rate of patients with CHF of NYHA (New York Heart Association) functional class II and III by observing the combined case as clinical indicator of survival rate. A combined case is defined as the total of death outcomes due to cardiovascular reasons regardless of its grounds and hospital treatments.
Methods
The CHF diagnosis was set based on the guideline of the European Society of Cardiology’s Task Force for Diagnosis and Treatment of Chronic Heart Failure [6]. Echocardiografic examination was performed according to the standardized assessment protocol of American Society of Echocardiography [11]. The criteria for including in the study were: age of 70 years or less, NYHA functional class II and III, left ventricular ejection fraction ≤40%. The criteria for excluding from the study were: systolic blood pressure of 100 mm Hg or less, bradicardia (heart frequency of up to 60 beats per minute) and all degrees of atrioventricular block or sinoatrial node disease, instable angina or myocardial infarct in the last three months, percutan coronar intervention or aortocoronary bypass in the last six months, obstructive or restrictive cardiomyopathies, congenital heart disorder, primary valvular disease or artificial valves, terminal diseases of other systems or organs, all known contraindications to beta-blockers application and the information about current treatment by β blockers. Patients were divided into three numerically equal therapeutic groups: patients treated by ACE inhibitor and diuretic – the control group (50 patients), patients treated by atenolol, ACE inhibitor and diuretic – the atenolol group (50 patients) and patients treated by metoprolol, ACE inhibitor and diuretic – the metoprolol group (50 patients).
The study was comparative, prospective and randomised. β blockers application start was determined by the phase when a patient was clinically ”dry” for two weeks. The initial atenolol dose was 25 mg once daily and initial dose of metoprolol tartrate was 25 mg divided in two daily doses. Farther titrational scheme was individual; target dose for both atenolol and metoprolol was 100 mg daily. The therapeutic effect has been followed for 12 months. The control examinations were performed after 1, 3, 6 and 12 months from start of the treatment. The study has been ongoing for 39 months. At each control we followed: possible negative effects of the β blockers treatment (symptomatic aggravation of CHF, symptomatic hypotension, symptomatic bradycardie), new cardiovascular diseases and new additional diseases independent of the cardiovascular system, bad compliance, death of a patient regardless of the cause. During the study we excluded from examinations all patients who had permanently discontinued intake of β blockers due to bad compliance or due to new additional disease independent of the cardiovascular system.
The statistical analyses were performed in the SPSS 10.0 program package and they comprised: X2-test, analysis of variance for investigation of differences in demographic characteristics and frequency of unfavorable events, Kaplan-Meier survival model curve for distribution of combined cases as function of time, equality test performed by log-rank statistics, Wilcoxon statistics for the determination of survival rate between two patients groups, Cox regression model FW (Forward Wald) for examination of relative risk for occurrence of combined case in the three groups of patients. In the beginning of study there were no significant differences in age, gender, systolic blood pressure and heart frequency, etiology CHF, NYHA class, ejection fraction, i.e. other diseases as hypertension and diabetes, between the CHF patients from three therapeutic groups (Table 1).
Results
The differences in deaths rates between the examined CHF patients groups were not statistically significant (Table 2). A statistical significant difference among the patients from the three therapeutic groups was found in the number (frequency) of hospitalisations due to cardiovascular diseases and in the number (frequency) of the combined cases. Frequency of hospitalisation in the metoprolol group (4%) was significantly less compared to the atenolol group (12%) and compared to the control group (26.3%). Combined case frequency in the metoprolol group (8%) was significantly less compared to the atenolol group (16%) and compared to the control group (26.3%) (Table 2). Kaplan-Meier’s survival rate curves were significantly different for different therapeutic groups of patients (log-rank 16.46; df=2; p=0.0003) as shown in the Graph 1. In the end of investigation the cumulative survival rate in the metoprolol group was 0.88 (88%), in the atenolol group 0.78 (78%) and in the control group 0.48 (48%). The survival rate of patients treated by atenolol was significantly greater compared to control group while the survival rate of patients treated by metoprolol was significantly greater compared to the control group as well compared to patients treated by atenolol (Table 3). It was determined that metoprolol significantly reduces the relative risk for emerging of combined cases (71.3%; ExpB 0.287; p=0.020) compared to atenolol (53.4%; ExpB 0.466; p=0.050). In the end of the study average daily doses of atenolol were 50±12.25 mg and average daily doses of metoprolol were 65.50±20 mg.
Discussion
Results of our study are further confirmation of the β1 selective antagonists’ favorable effect on development and outcome of chronic heart failure. The ground for this favorable effect lies in the deformations of adrenergic signaling in insufficient myocardium [1, 12]. A long and intensified stimulation by catecholamines leads to devastating biological effects on the myocytes level due to stimulation of β adrenergic receptors. These effects cause remodeling signals and evolution of malignant arrhythmia [12, 13]. As the ratio of β1 receptors and β2 receptors in the heart ventricles is 80:20% and due to the fact that noradrenalin performs its effects mainly through the β1 receptors, the adaptation of myocytes against the exaggerated stimulation happens foremost by reducing the number and sensitivity of β1 receptors. Another adaptive response of the myocytes is stimulation of iRNA and β adrenoceptor kinase (β-ARK) activities, as well as stimulation of activity of inhibitory subunit guanin-protein (Gi), what causes phosphorylisation of β receptors and prevents connecting to agonist (so called, functional uncoupling). These transformations in β adrenergic signaling explicitly disturb ability of the heart to increase its contractility to meet the hemodynamic needs. Application of the β1 blockers establishes a beneficial balance in so called cross-talk of the β1 and β2 receptor molecules, as proved in many studies [12-16]. The primary aims of the large studies as the total or cardiovascular mortality, cardiovascular morbidity or hospitalisation due to CHF progression and combined cases, have proved as acceptable clinical indicators of survival rate. More than 90% of the patients who were treated by β blockers, from the studies performed so far, had been previously treated by ACE inhibitor and diuretic [17, 18]. Reports from all finished studies confirm that β blockers significantly reduce mortality and morbidity. Results of our study are just another contribution to the previous studies. The most recent meta-analysis of the β blockers in CHF, published in 2000, includes 22 randomised, placebo-controlled studies, comprising more than 10,000 patients. The authors have concluded that treatment by β blockers reduces occurrence of combined case (the total mortality and hospitalisation due to CHF) by almost a 100% among the patients of NYHA class II and III. What practically means 3.8 saved lives out of 100 treated patients. At the same time β blockers reduce number of hospitalisations by four out of a 100 treated patients [1, 19]. The main question is do different β blockers have a significantly different effect on the CHF patient’s survival rate.
Results from the biggest comparative study (COMET) as well as the other smaller studies show that carvedilol has a more favorable effect on the survival rate than metoprolol. Number of death outcomes by all causes in the COMET study was significantly lower among the carvedilol patients group (34%) compared to the metoprolol group (40%), but numbers of the combined cases (death and hospital treatments regardless of its grounds) were not significantly different between patients treated by carvedilol (74%) and metoprolol (76%) [9]. The assumption that carvedilol’s ”advantage” over metoprolol lies ”outside” β1 blockade was disturbed by the observation that extent of β1 blockade by metoprolol (tartrate formulation, average daily dose 85 mg) in the COMET study was significantly lower than in the previous studies in which patients were treated by metoprolol. This observation impels carefulness while estimating some β blockers’ ”advantage” and opens a question about dosage and formulation of the medicine in other comparative studies, regardless of applied β blocker [20].
In our study we compared the effects of metoprolol-tartrate, a β1 blocker, with another β1 blocker – atenolol. This way we observed the effects of adrenoreceptor antagonists on combined case only within the β1 blockade. The both β1 blockers showed positive effect on the clinical development and outcome of CHF among the patients from the control group. While the effect of metoprolol (tartrate formulation, average daily dose 65.50±20 mg) was significantly better compared to atenolol’s effect (average daily dose 50±12.25 mg). It is possible that reasons for the variance could be connected to the different moduling of β adrenergic signaling. Namely, metoprolol has dominant β1 receptor activity and proved ability to recover the number and sensitivity of β1 adrenoreceptors [12]. Regardless of the negative inotropic effect, metoprolol in some way makes the β2 receptors sensible, redirects adrenergic signaling towards the β2 receptors, normalises the β-ARK and Gi activity and puts into balance the receptorial stimulation and inhibition of myocytes [1, 12, 21, 22]. Atenolol normalises β1 adrenergic signaling as well. But the β1 and β2 receptorial activities ratio is much greater. The expected result of such receptorial activity could be symptomatic bradycardia or symptomatic deterioration of CHF i.e. reduced drug tolerance. Which mechanisms initiate the favorable and which initiate the unfavorable occurrences during the β1 blockade is not clear yet [1, 21, 22]. Metoprolol tartrate, unlike atenolol, is liposoluble i.e. can easily pass emato-encefalic barrier. It has been proved that its primarily effect can prevent occurrence of lethal arrhythmia [23]. All the stated influences that metoprolol has on adrenergic signaling can – to some extend – explain the better tolerance and more favorable effects of metoprolol on the survival rate of patients with mild-to-moderate CHF, compared to atenolol, even though the molecular mechanisms that lie as a ground for the different effects of these β blockers of the same generation, are for the time being not sufficiently investigated.
Conclusion
In patients with chronic heart failure NYHA functional class II and III of different etiologies, previously treated by ACE inhibitors and diuretics, both of the β1 blockers (metoprolol-tartrate and atenolol) reduce the total mortality and cardiovascular morbidity compared to the control group of patients, while the metoprolol’s effect on the survival rate is significantly better and the application safer compared to the effect and application of atenolol.
Literature
1. Hermann DD. Beta-adrenergic blockade 2002: A pharmacologic
odyssey in chronic heart failure. CHF 2002; 8(5):262-9.
2. Bristow MR. Why does the myocardium fail? Insights from basic
science. Lancet 1998; 352(Suppl I):8-14.
3. SOLVD Investigators. Effect of enalapril on survival in patients
with reduced left ventricular ejection fraction and congestive heart
failure. N Engl J Med 1991; 325:293-302.
4. CONSENSUS Trial Study Group. Effects of enalapril on mortality
in severe congestive heart failure: results of the Cooperative North
Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J
Med 1987; 316(23):1429-35.
5. MetraM, Nodari S, D’AloiaA, et al. A rationale for the use of betablockers
as standard treatment for heart failure. Am Heart J 2000;
139(3):511-21.
6. The Task Force for the Diagnosis and Treatment of Chronic Heart
Failure, European Society of Cardiology. Guidelines for the diagnosis
and treatment of chronic heart failure. Eur Heart J 2001;
22:1527-60.
7. Adams KF.Which beta blocker for heart failure? Am Heart J 2001;
141:884-8.
8. Bristow MR.What type of beta blocker should be used to treat
chronic heart failure. Circulation 2000; 102:484-6.
9. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of
carvedilol and metoprolol on clinical outcomes in patients with
chronic heart failure in the Carvedilol Or Metoprolol European
Trial (COMET): randomised controlled trial. Lancet 2003;
362(9377):7-13.
10. Metra M, Giubbini R, Nodari S, et al. Differential effects of betablockers
in patients with heart failure: a prospective, randomized,
double-blind comparison of the long-term effects of metoprolol
versus carvedilol. Circulation 2000; 102:546-51.
11. Shiller N, Shah PM, Crawford M, et al. Recommendations for
quantitation of the left ventricle by two dimensional echocardiography.
J Am Soc Echocardiography 1989; 2:358-68.
12. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in
the human heart. Pharmacological Reviews 1999; 51(4):651-90.
13. Remme WJ. The sympatetic nervous system and ischaemic heart
disease. Eur Heart J 1998; 19(Suppl F):F62-F71.
14. Ceconi C, Curello S, Ferrari R. The neuroendocrine and sympathetic
nervous systemin congestive heart failure. Eur Heart J 1998;
19(Suppl F):F45-F51.
15. Liggett SB. β-adrenergic receptors in the failing heart: the good, the
bad, and the unknown. J Clin Invest 2001; 8:947-8.
16. Houser SR, Margulies KB. Is depresed myocyte contractility centrally
involved in heart failure? Circ Res 2003; 92:350-8.
17. Eichhorn EJ. Experience with beta blockers in heart failure mortality
trials. Clin Cardiol 1999; 22:(Suppl V):V21-V29.
18. Lechat P, Packer M, Chalon S, et al. A meta-analysis of doubleblind,
placebo-controlled, randomized trials. Circulation 1998;
98:1184-91.
19. Brophy JM, Joseph L, Ruleau JL. Beta blockers in congestive heart
failure. A Bayesian meta-analysis. Ann Intern Med 2001;
134:550-60.
20. Dogrell SA. Has COMET solved the controversy as to whether
carvedilol is better than metoprolol in heart failure. Expert Opinion
on Pharmacotherapy 2004; 5(1):205-8.
21. BristowMR.Mechanismof action of beta-blocking agents in heart
failure. Am J Cardiol 1997; 80:26L-40L.
22. Sabbah HN. The celluar and physiologic effects of beta blockers in
heart failure. Clin Cardiol 1999; 22(Suppl V):V16-V20.
23. Hjalmarson A. Prevention of sudden cardiac death with beta
blockers. Clin Cardiol1999; 22(Supll V):V11-V15.
Bengt Åblad comment: This interesting paper contains three tables and one figure ( see below).
Etiketter: chronic heart failure, survival rate, therapeutic groups
september 30, 2012 kl. 2:04 e m |
Hey! I know this is kinda off topic but I’d figured I’d ask.
Would you be interested in trading links or maybe guest authoring a
blog post or vice-versa? My blog covers a lot of
the same subjects as yours and I believe we could greatly
benefit from each other. If you might be interested feel free to send me an
email. I look forward to hearing from you! Terrific blog by the way!
september 30, 2012 kl. 5:42 e m |
Glad for your interest in our work. Hope we will have further contact.
oktober 6, 2012 kl. 11:29 f m |
Fabulous, what a webpage it is! This weblog presents
helpful data to us, keep it up.
december 3, 2012 kl. 7:09 e m |
Attractive element of content. I just stumbled upon your blog and in accession capital to claim that I acquire actually
enjoyed account your blog posts. Anyway I will be subscribing in your augment or even I success you get right
of entry to constantly quickly.
januari 3, 2013 kl. 2:13 f m |
Hello, this weekend is nice designed for me, as this time i am reading this impressive informative paragraph here
at my house.
januari 15, 2013 kl. 4:13 e m |
Heya i am for the first time here. I found this board and I in finding It truly useful & it helped me out a lot.
I’m hoping to offer something again and aid others like you aided me.
februari 16, 2013 kl. 8:23 f m |
Unquestionably imagine that that you stated. Your
favorite reason appeared to be on the internet the simplest thing to understand of.
I say to you, I certainly get annoyed while other folks think about issues that they just don’t realize about. You controlled to hit the nail upon the top as neatly as outlined out the entire thing with no need side effect , other folks can take a signal. Will probably be again to get more. Thanks
mars 3, 2013 kl. 10:20 f m |
Definitely believe that which you said. Your favorite
reason appeared to be on the internet the simplest
thing to be aware of. I say to you, I definitely get irked while people think about worries that they just do
not know about. You managed to hit the nail upon the top and also defined out the whole thing without having side-effects , people
can take a signal. Will likely be back to get more. Thanks
mars 4, 2013 kl. 10:55 f m |
Howdy! Quick question that’s completely off topic. Do you know how to make your site mobile friendly? My weblog looks weird when browsing from my apple iphone. I’m trying to find
a theme or plugin that might be able to fix this problem.
If you have any recommendations, please share. With thanks!
april 10, 2013 kl. 3:48 f m |
If some one wants expert view concerning blogging afterward i advise him/her to go to see
this weblog, Keep up the fastidious work.
april 21, 2013 kl. 9:33 e m |
It’s an remarkable article in favor of all the web visitors; they will obtain benefit from it I am sure.
april 30, 2013 kl. 10:05 e m |
Useful information. Lucky me I discovered your web site accidentally, and I am stunned why this twist of fate
did not happened in advance! I bookmarked it.
april 30, 2013 kl. 10:32 e m |
Hi there to every one, the contents existing at this web site
are truly awesome for people experience, well, keep up
the nice work fellows.
maj 3, 2013 kl. 1:30 f m |
I enjoy what you guys are up too. This kind of clever work and reporting!
Keep up the terrific works guys I’ve added you guys to my own blogroll.
maj 11, 2013 kl. 1:00 f m |
If you desire to grow your knowledge just keep visiting this site and be updated with the hottest gossip posted here.
maj 12, 2013 kl. 2:30 f m |
Pretty section of content. I just stumbled upon your site and
in accession capital to assert that I get
in fact enjoyed account your blog posts. Any way I’ll be subscribing to your augment and even I achievement you access consistently quickly.
maj 24, 2013 kl. 8:38 f m |
Admiring the commitment you put into your site
and in depth information you offer. It’s good to come across a blog every once in a while that isn’t the same unwanted rehashed information.
Excellent read! I’ve bookmarked your site and I’m adding your RSS feeds to my Google account.
maj 27, 2013 kl. 8:24 e m |
Great post. I was checking continuously this blog
and I am impressed! Very useful information specially the last part 🙂 I care
for such info a lot. I was looking for this particular info for a long time.
Thank you and good luck.
maj 29, 2013 kl. 5:05 f m |
Hey, I think your blog might be having browser compatibility issues.
When I look at your blog in Chrome, it looks fine
but when opening in Internet Explorer, it has some overlapping.
I just wanted to give you a quick heads up! Other then that, very good blog!
juni 20, 2013 kl. 12:51 f m |
Heya i am for the first time here. I came across this board and I find
It really useful & it helped me out a lot. I hope to give something back and help others like you helped me.
augusti 11, 2013 kl. 6:14 f m |
My pal advised I could such as this web site. Your dog has been totally proper. This kind of submit basically built my personal time. You cannot envision the amount of time I needed invested with this information and facts! Thanks a lot!
september 21, 2013 kl. 2:49 f m |
Typically I really don’t understand posting on sites, having said that i want to express that this kind of write-up quite forced my family to think about as well as achieve this! A person’s publishing preference continues to be stunned my family. Appreciate it, pretty good post.
december 28, 2013 kl. 10:02 f m |
Wonderful website. A lot of useful information here. I’m sending it to some pals ans additionally sharing in delicious.
And certainly, thanks to your effort!
februari 6, 2014 kl. 10:37 e m |
Hello, i think that i saw you visited my website thus i came to “return the favor”.I am attempting to find things to improve my website!I suppose its ok to use
a few of your ideas!!
februari 9, 2014 kl. 10:23 f m |
It’s an amazing article designed for all the online people; they will take advantage
from it I am sure.
februari 12, 2014 kl. 1:05 f m |
I could nnot resist commenting. Verry well written that I read this evening and I do love it.
But also, in my view,I think you could write it better if you can add more pictures at beginning.
At this moment I am ready to do my breakfast, afterward having my breakfast coming yet again too read further news.
februari 21, 2014 kl. 7:21 f m |
Awesome! Its genuinely awesome piece of writing,
I have got much clear idea about from this paragraph.
mars 4, 2014 kl. 1:01 e m |
Good information. Lucky me I found your blog by accident
(stumbleupon). I have saved as a favorite for later!
mars 5, 2014 kl. 3:49 f m |
Excellent post. I was checking continuously this
blog and I am impressed! Very useful info particularly the last part 🙂 I care for such information a lot.
I was looking for this certain info for a long time.
Thank you and best of luck.
mars 8, 2014 kl. 5:30 f m |
Very great post. I just stumbled upon your blog and wanted to mention that I have truly enjoyed surfing around your weblog posts.
After all I will be subscribing on your feed and I’m hoping
you write again soon!
mars 17, 2014 kl. 9:34 e m |
Thanks for ones marvelous posting! I quite enjoyed reading it, you can be a great author.I will
make sure to bookmark your blog and may come back down
the road. I want to encourage you to definitely continue your great
job, have a nice holiday weekend!
mars 22, 2014 kl. 5:14 f m |
I have learn some excellent stuff here. Definitely value bookmarking for revisiting.
I wonder how much effort you set to create the sort of fantastic informative site.
mars 25, 2014 kl. 11:47 f m |
Hi there! I simply want to offer you a huge thumbs up for your great info you’ve got right here on this
post. I will be coming back to your blog for more soon.
mars 26, 2014 kl. 11:21 f m |
Hi there! I could have sworn I’ve been to this website before but after checking through some of the post
I realized it’s new to me. Anyhow, I’m definitely delighted I found it
and I’ll be book-marking and checking back frequently!
mars 28, 2014 kl. 6:08 e m |
Hi there, just wanted to tell you, I loved this article.
It was helpful. Keep on posting!
april 5, 2014 kl. 6:25 e m |
Great website. A lot of helpful info here. I’m sending it to some
pals ans also sharing in delicious. And obviously, thanks in your effort!
april 20, 2014 kl. 4:03 f m |
Hey I know this is off topic but I was wondering if you knew
of any widgets I could add to my blog that
automatically tweet my newest twitter updates. I’ve been
looking for a plug-in like this for quite some time and was hoping maybe you would have some experience with something like this.
Please let me know if you run into anything. I truly enjoy reading your blog and I look forward to your new updates.
april 30, 2014 kl. 12:26 e m |
If some one desires expert view concerning blogging afterward i advise him/her to pay a quick visit this website, Keep
up the nice work.
maj 1, 2014 kl. 8:28 e m |
Thanks on your marvelous posting! I genuinely enjoyed reading it, you
may be a great author. I will always bookmark your blog and will often come back later in life.
I want to encourage yourself to continue your great posts, have a nice
holiday weekend!
maj 8, 2014 kl. 6:05 f m |
Excellent website. Plenty of useful information here. I’m
sending it to several buddies ans also sharing in delicious.
And certainly, thanks for your sweat!
maj 9, 2014 kl. 8:41 f m |
Hi! Do you use Twitter? I’d like to follow you if that would be ok.
I’m undoubtedly enjoying your blog and look forward to
new updates.
maj 22, 2014 kl. 8:01 e m |
You could certainly see your enthusiasm in the work you
write. The sector hopes for even more passionate writers like you who are not
afraid to mention how they believe. All the time follow your heart.
maj 26, 2014 kl. 5:03 e m |
Have you ever thought about adding a little bit more than just your articles?
I mean, what you say is fundamental and everything.
But think of if you added some great images or video clips to give your posts more,
”pop”! Your content is excellent but with images and videos, this blog could undeniably be one of the most beneficial in its field.
Awesome blog!
juni 17, 2014 kl. 7:58 f m |
Generally I don’t learn article on blogs, but I would like
to say that this write-up very compelled me to take a look at and do it!
Your writing taste has been amazed me. Thanks, quite nice post.
juni 17, 2014 kl. 12:12 e m |
Hello! Do you use Twitter? I’d like to follow you if that
would be ok. I’m absolutely enjoying your blog and look forward to new
updates.
juni 26, 2014 kl. 5:48 e m |
Amazing blog! Is your theme custom made or did you download it from
somewhere? A design like yours with a few simple tweeks would really make my blog
stand out. Please let me know where you got your theme.
Cheers
juni 30, 2014 kl. 8:09 f m |
I got this web site from my buddy who told me on the topic of
this web site and now this time I am browsing this web site and reading very informative content at this place.
juli 3, 2014 kl. 7:58 f m |
Very nice post. I just stumbled upon your weblog and wanted to say that I’ve really enjoyed surfing around your blog posts.
In any case I’ll be subscribing to your feed and I hope you write again very soon!
juli 6, 2014 kl. 6:38 f m |
May I simply just say what a comfort to find somebody who really understands
what they’re discussing on the web. You definitely know
how to bring a problem to light and make it important.
More people need to check this out and understand this side of the story.
I was surprised that you are not more popular since you
most certainly possess the gift.
juli 9, 2014 kl. 3:41 e m |
Hey there! I’ve been following your site for a while now and finally got the
bravery to go ahead and give you a shout out
from Atascocita Texas! Just wanted to say keep up the good job!
juli 21, 2014 kl. 7:15 f m |
Hey there! I’ve been following your site for a while now and finally got the
bravery to go ahead and give you a shout out
juli 21, 2014 kl. 7:15 f m |
what they’re discussing on the web. You definitely know
how to bring a problem to light and make it important.
juli 21, 2014 kl. 7:16 f m |
Amazing blog! Is your theme custom made or did you download it from
somewhere? A design like yours with a few simple tweeks would really make my blog
juli 22, 2014 kl. 11:28 e m |
I’m not sure where you are getting your information, but great topic.
I needs to spend some time learning more or understanding more.
Thanks for excellent information I was looking for this information for my
mission.
juli 31, 2014 kl. 10:16 e m |
Hi there to all, how is the whole thing, I think every one is getting more from this web page, and your views
are pleasant for new viewers.
augusti 4, 2014 kl. 5:56 e m |
Hurrah! In the end I got a blog from where I can genuinely get helpful
facts regarding my study and knowledge.
augusti 7, 2014 kl. 7:49 f m |
I’m not that much of a internet reader to be honest but your blogs really nice, keep it
up! I’ll go ahead and bookmark your website to come back down the
road. All the best
augusti 7, 2014 kl. 11:51 f m |
I’m not sure where you’re getting your info, but good topic.
I needs to spend some time learning more or understanding more.
Thanks for excellent information I was looking for this information for my mission.
augusti 8, 2014 kl. 6:13 f m |
Excellent website. Plenty of helpful information here.
I’m sending it to a few pals ans additionally sharing in delicious.
And certainly, thank you on your effort!
augusti 11, 2014 kl. 5:31 f m |
Hello to every one, the contents present at this site are in fact
remarkable for people experience, well, keep up the nice
work fellows.
augusti 13, 2014 kl. 7:10 f m |
Hi, i believe that i saw you visited my web site thus i came to return the prefer?.I’m attempting to
in finding things to improve my web site!I assume its ok to make use of some of
your ideas!!
augusti 26, 2014 kl. 10:38 e m |
It’s going to be ending of mine day, however before ending I am reading this
wonderful piece of writing to increase my experience.
september 9, 2014 kl. 12:21 e m |
I will right away snatch your rss feed as I can’t find your e-mail subscription hyperlink or newsletter service.
Do you’ve any? Kindly allow me know so that I may subscribe.
Thanks.
september 16, 2014 kl. 1:14 f m |
garcinia morella
Metoprolol better than atenolol in therapy of cardiac failure! Role of peripheral NPY!? | Bengtablad’s Blog
september 24, 2014 kl. 8:19 e m |
I quite like looking through a post that can make people think.
Also, thank you for permitting me to comment!
oktober 1, 2014 kl. 12:00 f m |
I don’t even know how I ended up here, but I thought this post was great.
I don’t know who you are but defginitely you’re going to a famous blogger if yoou aren’t already 😉 Cheers!
oktober 4, 2014 kl. 2:05 f m |
Very great post. I just stumbled upon your weblog and wished to say
that I have really enjoyed browsing your blog posts.
In any case I’ll be subscribing in your rss
feed and I hope you write once more soon!
oktober 6, 2014 kl. 2:53 f m |
Excellent site. Plenty of helpful info here. I am sending it to several pals
ans also sharing in delicious. And certainly,
thank you for your sweat!
oktober 23, 2014 kl. 6:22 e m |
I read this piece of writing fully concerning the difference of most recent
and earlier technologies, it’s awesome article.
december 11, 2014 kl. 7:58 e m |
Woah! I’m really enjoying the template/theme of this blog.
It’s simple, yet effective. A lot of times it’s very difficult to get that ”perfect balance” between user friendliness and visual
appeal. I must say you have done a superb job with this.
Also, the blog loads super quick for me on Opera.
Superb Blog!
december 28, 2014 kl. 5:46 e m |
This post is worth everyone’s attention. When can I find
out more?
februari 20, 2015 kl. 2:15 e m |
I’ve been surfing online greater than three hours nowadays, yet I never found any fascinating article like
yours. It’s beautiful value sufficient for me.
Personally, if all webmasters and bloggers made good content as you did, the web might be a
lot more useful than ever before.
maj 24, 2015 kl. 8:29 f m |
Amazing! Itss genuinely amazing paragraph, I ave got much clear
idfea regarding from this post.
november 22, 2015 kl. 11:01 e m |
I believe everything published was very logical.
But, what about this? suppose you were to create a killer headline?
I mean, I don’t wish to tell you how too run your blog, howevver
what iff you added a title hat makes people want more?
I mean Metoprolol better than atenolol in therapy of cardiac failure!
Role off peripheral NPY!? | Bengtablad’s Blog is kinda boring.
You should look at Yahoo’s front pae and watch how they create
post titles to get viewers interested. You might add a video or a related pic or ttwo tto get people interested about everything’ve written. In my
opinion, it could make your posts a little bit more
interesting.
juni 5, 2016 kl. 11:55 f m |
Your style is so unique compared to other people I have read stuff from.
Thank you for posting when you have the opportunity, Guess I
will just book mark this web site.
augusti 31, 2016 kl. 4:37 e m |
Your style is so unique in comparison to other folks I’ve read stuff from.
Many thanks ffor posring when you have the opportunity, Guess I will just book mark this page.
oktober 15, 2016 kl. 7:25 f m |
It’s in fact very complex in this active life to
listen news on TV, so I only use world wide web for that reason,
and get the latest information.
december 23, 2016 kl. 10:55 e m |
Excellent blog you have here.. It’s hard to find high-quality writing like
yours nowadays. I honestly appreciate people like you!
Take care!!
april 24, 2017 kl. 9:52 f m |
director
Metoprolol better than atenolol in therapy of cardiac failure! Role of peripheral NPY!? | Bengtablad's Blog
november 8, 2017 kl. 4:55 f m |
If some one needs to be updated with hottest technologies afterward he must be pay a visit this website and be
up to date daily.
november 18, 2017 kl. 8:27 e m |
gta 5 money generator no verification
Metoprolol better than atenolol in therapy of cardiac failure! Role of peripheral NPY!? | Bengtablad